Teva Pharmaceutical Industries Limited or Jazz Pharmaceuticals plc: Who Manages SG&A Costs Better?

Who Manages SG&A Costs Better: Teva or Jazz?

In the competitive pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, Jazz Pharmaceuticals plc and Teva Pharmaceutical Industries Limited have shown contrasting trends in their SG&A management. Jazz Pharmaceuticals has seen a steady increase in SG&A expenses, peaking at approximately 1.45 billion in 2021, a 257% rise from 2014. In contrast, Teva's SG&A expenses have decreased by about 31% over the same period, from 5.08 billion in 2014 to 3.50 billion in 2023. This suggests Teva's strategic focus on cost reduction, while Jazz's growth strategy might involve higher operational costs. Understanding these trends can provide insights into each company's operational efficiency and strategic priorities. As the pharmaceutical landscape evolves, monitoring these expenses will be key to assessing future financial health.